Here’s Why Genmab A/S (GMAB) Rose in Q3

1 day ago 2

Soumya Eswaran

Wed, December 31, 2025 astatine 7:43 AM CST 3 min read

Chautauqua Capital Management, a part of Baird Asset Management, is simply a boutique concern steadfast that released its third-quarter 2025 capitalist missive for the “Baird Chautauqua International and Global Growth Fund”. A transcript of the missive tin beryllium downloaded here. Global equity markets delivered coagulated results successful the 3rd quarter, driven by the solution of important commercialized conflicts and a displacement successful U.S. monetary argumentation toward a much dovish stance. Baird Chautauqua International Growth Fund underperformed the benchmark, MSCI ACWI ex-U.S. Index - ND, successful the quarter, driven by banal enactment successful the accusation technology, financials, and industrials sectors, which detracted the astir from returns. The Baird Chautauqua Global Growth Fund besides trailed the benchmark, MSCI ACWI Index – ND, successful the 4th arsenic banal enactment successful the accusation technology, financials, and industrials sectors detracted the astir from returns. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Baird Chautauqua International and Global Growth Fund highlighted stocks specified arsenic Genmab A/S (NASDAQ:GMAB). Genmab A/S (NASDAQ:GMAB) is simply a biotechnology institution that focuses connected processing antibody-based products and merchandise candidates for the attraction of crab and different diseases. The one-month instrumentality of Genmab A/S (NASDAQ:GMAB) was -0.69%, and its shares gained 50.89% of their worth implicit the past 52 weeks. On December 30, 2025, Genmab A/S (NASDAQ:GMAB) banal closed astatine $31.49 per share, with a marketplace capitalization of $19.522 billion.

Baird Chautauqua International and Global Growth Fund stated the pursuing regarding Genmab A/S (NASDAQ:GMAB) successful its 3rd 4th 2025 capitalist letter:

" Genmab A/S (NASDAQ:GMAB) reported coagulated net and announced affirmative Epkinly signifier III and signifier II objective proceedings results. Its pipeline merchandise campaigner Rina-S received FDA Breakthrough Therapy Designation successful precocious endometrial cancer."

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

Genmab A/S (NASDAQ:GMAB) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 20 hedge money portfolios held Genmab A/S (NASDAQ:GMAB) astatine the extremity of the 3rd quarter, up from 19 successful the erstwhile quarter. While we admit the imaginable of Genmab A/S (NASDAQ:GMAB) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.